

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John W. Hess et al.



Serial No. 10,573,926

Filed: March 30, 2006

For: TRANSGENIC RODENTS SELECTIVELY
EXPRESSING HUMAN B1 BRADYKININ RECEPTOR
PROTEINArt Unit: to be assignedExaminer: to be assignedCommissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By C. Rapacki Date 3-30-07

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,


 By: Henry P. Wu

Attorney _____ For Applicant(s)

Reg. No. 44,412

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-5312


Date: March 30, 2007

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

**COMPLETE IF KNOWN**

Application Number	10/573,926
Filing Date	March 30, 2006
First Named Inventor	John W. Hess
Group Art Unit	to be assigned
Examiner Name	to be assigned
Attorney Docket Number	21394YP

Sheet

1

of

2

Attorney Docket Number 21394YP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


[illegible]

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		COMPLETE IF KNOWN	
Application Number		10/573,926	
Filing Date		March 30, 2006	
First Named Inventor		John W. Hess	
Group Art Unit		to be assigned	
Examiner Name		to be assigned	
Sheet 2	of 2	Attorney Docket Number 21394YP	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	C01	Bock et al. "'Bradykinin antagonists: new opportunities', Current Opinion in Chemical Biology", Vol. 4, pp 401-406 (2000)
	C02	Bonaventure et al. "Humanization of Mouse 5-Hydroxytryptamine 1B Receptor Gene by Homologous Recombination: In Vitro and In Vivo Characterization", Molecular Pharmacology, Vol. 56, pp 54-67 (1999)
	C03	Dray and Perkins, "Bradykinin and Inflammatory Pain", TINS, Vol. 16, No. 3, pp 99-10 (1993)
	C04	GenBank Accession No. BC034705 (2002)
	C05	GenBank Accession No. NM_007539 (2002)
	C06	Hess et al. "The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors", Immunopharmacology, Vol. 33, pp 1-8 (1996)
	C07	Hess et al. "Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor", Biochemical and Biophysical Research Communications, Vol. 184, No. 1, pp 260-268 (1992)
	C08	Jones et al. "Molecular characterisation of cloned bradykinin B1 receptors from rat and human", European Journal of Pharmacology, Vol. 374, pp 423-433 (1999)
	C09	MacNeil et al. "Cloning and pharmacological characterization of a rabbit bradykinin B1 receptor", Biochimica et Biophysica Acta, Vol. 1264, pp 223-228 (1995)
	C10	McEachern et al. "Expression cloning of a rat B2 bradykinin receptor", Proc. Natl. Acad. Sci. USA Vol. 88, pp 7724-7728 (1991)
	C11	Menke et al. "Expression Cloning of a Human B1 Bradykinin Receptor", Journal of Biological Chemistry, Vol. 269, No.34, Issue of August 26, pp 21583-21586 (1994)
	C12	Milstone et al. "Simultaneous Cre Catalyzed Recombination of Two Alleles to Restore Neomycin Sensitivity and Facilitate Homozygous Mutations", Nucleic Acids Research, Vol. 27, No. 15, pp 1-3 (1999)
	C13	Pesquero et al. "'Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors", Proc. Natl. Acad. Sci. USA, Vol. 97, No. 14, pp 8140-8145 (2000)
	C14	Pesquero et al. "Molecular Cloning and Functional Characterization of a Mouse Bradykinin B1 Receptor Gene", Biochemical and Biophysical Research Communications, Vol. 220, pp 219-225 (1996)
	C15	Proud and Kaplan, "Kinin Formation: Mechanisms and Role in Inflammatory Disorders", Annual Review Immunology, Vol. 6, pp 49-83 (1988)

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006